Physician profile
Nathaniel A Keller
NPI 1144411844
$12,007.69
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $81.40 · 2021: $14.20.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $11,115.01 | 2019 | |
| Allergan, INC. | $237.60 | 2019-2020 | |
| Bausch Health US, LLC | $158.04 | 2019 | |
| Lundbeck LLC | $131.77 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $89.35 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $80.53 | 2019 | |
| Ironshore Pharmaceuticals INC. | $47.65 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $33.24 | 2019 | |
| Brainsway USA INC | $24.16 | 2019 | |
| Shire North American Group INC | $23.06 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $20.24 | 2019 | |
| Rhodes Pharmaceuticals L.P. | $19.44 | 2019 | |
| Jazz Pharmaceuticals INC. | $14.20 | 2021 | |
| Neuronetics, INC. | $13.40 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathaniel Keller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.